HRP20211371T1 - Stabilne, vodene formulacije protutijela - Google Patents
Stabilne, vodene formulacije protutijela Download PDFInfo
- Publication number
- HRP20211371T1 HRP20211371T1 HRP20211371TT HRP20211371T HRP20211371T1 HR P20211371 T1 HRP20211371 T1 HR P20211371T1 HR P20211371T T HRP20211371T T HR P20211371TT HR P20211371 T HRP20211371 T HR P20211371T HR P20211371 T1 HRP20211371 T1 HR P20211371T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- antibody
- stable
- antibody formulations
- aqueous antibody
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (4)
1. Stabilna vodena formulacija protutijela koja nije podvrgnuta temperaturama smrzavanja, koja sadrži:
a. 30 mg/mL protutijela, pri čemu protutijelo sadrži teški lanac koji sadrži SEQ ID NO: 4 i laki lanac koji sadrži SEQ ID NO: 2; i
b. 0.006% polisorbata-20; i
c. 20 mM histidin/histidin HCl; i
d. 250 mM trehaloze, pri čemu formulacija ima pH 6.0.
2. Formulacija protutijela u skladu s patentnim zahtjevom 1, naznačena time što je formulacija, formulacija koja se može ubrizgati, po izboru pri čemu je formulacija pogodna za intravensku, potkožnu, ili intramuskularnu primjenu.
3. Zatvoreni spremnik naznačen time što sadrži formulaciju protutijela prema zahtjevu 1 ili 2.
4. Farmaceutski jedinični oblik doziranja prikladan za parenteralnu primjenu kod čovjeka, koji sadrži formulaciju protutijela prema bilo kojem od patentnih zahtjeva 1 do 3 u prikladnom spremniku, po izboru gdje je prikladni spremnik napunjena štrcaljka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 | |
| EP14855343.1A EP3060229B1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
| PCT/US2014/061997 WO2015061584A1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211371T1 true HRP20211371T1 (hr) | 2021-11-26 |
Family
ID=52993565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211371TT HRP20211371T1 (hr) | 2013-10-24 | 2021-08-30 | Stabilne, vodene formulacije protutijela |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20150118249A1 (hr) |
| EP (2) | EP3892288A1 (hr) |
| JP (3) | JP6483673B2 (hr) |
| KR (3) | KR102109053B1 (hr) |
| CN (3) | CN112107538A (hr) |
| AU (3) | AU2014339984B2 (hr) |
| BR (1) | BR112016008576B1 (hr) |
| CA (1) | CA2926089C (hr) |
| CY (1) | CY1125697T1 (hr) |
| DK (1) | DK3060229T3 (hr) |
| ES (1) | ES2893861T3 (hr) |
| HK (1) | HK1221900A1 (hr) |
| HR (1) | HRP20211371T1 (hr) |
| HU (1) | HUE055919T2 (hr) |
| LT (1) | LT3060229T (hr) |
| MX (2) | MX2016004605A (hr) |
| PL (1) | PL3060229T3 (hr) |
| PT (1) | PT3060229T (hr) |
| RS (1) | RS62419B1 (hr) |
| RU (2) | RU2763787C2 (hr) |
| SG (2) | SG11201603206UA (hr) |
| SI (1) | SI3060229T1 (hr) |
| WO (1) | WO2015061584A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
| US9159537B2 (en) * | 2012-05-03 | 2015-10-13 | University Of Notre Dame Du Lac | Method for analyzing sample components |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| MX2016004605A (es) * | 2013-10-24 | 2016-11-14 | Astrazeneca Ab | Formulaciones de anticuerpos estables acuosas. |
| CA2938946A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
| CA2998716A1 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED AMINO ACID AND SUGAR REPORTS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS |
| KR102037041B1 (ko) * | 2016-08-10 | 2019-10-29 | (주)셀트리온 | 항-인플루엔자 바이러스 항체의 안정한 액체 약제학적 제제 |
| CN109982685B (zh) * | 2016-10-21 | 2022-03-11 | 美国安进公司 | 药物配制品及其制备方法 |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| JPWO2021124793A1 (hr) * | 2019-12-16 | 2021-06-24 | ||
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| AU2021233503A1 (en) * | 2020-03-13 | 2022-09-22 | Samsung Bioepis Co., Ltd. | Liquid pharmaceutical composition having improved stability |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| IL303744A (en) * | 2020-12-17 | 2023-08-01 | Astrazeneca Ab | ANTI-IL5R formulations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| DK0574395T3 (da) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JP3946256B2 (ja) * | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン５受容体α鎖に対する抗体 |
| JP4308249B2 (ja) * | 2003-05-26 | 2009-08-05 | ビャク，ウー・イン | 使い捨て式注射器 |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| MX2008013508A (es) * | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| US20100209434A1 (en) * | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| KR101588061B1 (ko) | 2007-05-14 | 2016-01-25 | 메디뮨 엘엘씨 | 호산구 수준을 감소시키는 방법 |
| PE20110302A1 (es) * | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
| EP2403874A1 (en) * | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
| SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| MX2014004725A (es) * | 2011-10-18 | 2015-02-05 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con aminoacidos. |
| WO2013062841A1 (en) * | 2011-10-26 | 2013-05-02 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents in mixed mode chromatography |
| CN104023748B (zh) * | 2011-10-28 | 2018-03-02 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| WO2013066780A2 (en) * | 2011-11-01 | 2013-05-10 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| RS61565B1 (sr) * | 2013-08-12 | 2021-04-29 | Astrazeneca Ab | Postupci za povećanje forsiranog ekspiratornog volumena kod astmatičara korišćenjem benralizumaba |
| PL3033101T3 (pl) * | 2013-08-12 | 2019-06-28 | Astrazeneca Ab | Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu |
| MX2016004605A (es) * | 2013-10-24 | 2016-11-14 | Astrazeneca Ab | Formulaciones de anticuerpos estables acuosas. |
-
2014
- 2014-10-23 MX MX2016004605A patent/MX2016004605A/es unknown
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active IP Right Grant
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active IP Right Grant
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 CN CN201480055263.0A patent/CN105611938A/zh active Pending
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en active Application Filing
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Application Discontinuation
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
- 2016-08-23 HK HK16110007.2A patent/HK1221900A1/zh unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US20190201535A1/en active Pending
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-08-30 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20211415T1 (hr) | Brzodjelujući pripravci inzulina | |
| HRP20191199T1 (hr) | Formulacije protutijela anti-prolaktinskog receptora | |
| HRP20191827T1 (hr) | Formulacija protutijela | |
| JP2018523676A5 (hr) | ||
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| BR112018005349A2 (pt) | preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| MX344727B (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| HRP20220692T1 (hr) | Brzodjelujući pripravci inzulina | |
| HRP20212014T1 (hr) | Spoj peptida | |
| HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
| ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| BR112015016930A2 (pt) | formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina | |
| HRP20180040T1 (hr) | Lijek za prevenciju i/ili liječenje policistične bolesti bubrega | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| BR112015015864A2 (pt) | composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica | |
| BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
| EA201790872A1 (ru) | Фиксирующий механизм теплового действия для устройства доставки лекарственного средства | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| CY1121791T1 (el) | Καινοτομος σταθερη φαρμακοτεχνικη μορφη | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії |